secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003929
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics outlines 2024 milestones: paltusotine Phase 3 data Q1, CRN04894 data Q2
--------------------------------------------------------------------------------

- Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly on track for topline data in Q1 2024.
- Phase 2 trial of paltusotine in carcinoid syndrome topline data expected H1 2024; Phase 3 start H2 2024.
- Phase 2 trials of CRN04894 (ACTH antagonist) in CAH and Cushing's disease initial data expected Q2 2024.
- Preclinical evaluation ongoing for oral small molecules in hyperparathyroidism, PKD, Graves', TED, diabetes, and obesity.
- CEO to present at J.P. Morgan Healthcare Conference on Jan 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524003929/0001193125-24-003929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524003929/d706423d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer